Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Fig. 3

Subgroup analyses of PFS to Osimertinib. A Forest plot of hazard ratio (HR) and p value for ultivariate analyses of clinical subgroup. B Comparison of PFS between elder patients (≥ 65 years)and younger patients (< 65 years). C Comparison of PFS between patients of smoker and patients of non-smoker. D Comparison of PFS between patients with longer PFS1 (≥ 12 months) and patients with shorter PFS1 (< 12 months)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us